Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
PepGen Inc.
organization2 mentionslast seen Nov 12, 2026
Clinical-stage biotechnology company developing oligonucleotide therapies for rare genetic diseases.
Relationships 6
- PepGen Inc.developsPGN-EDODM199% confidence2 sources
- PepGen Inc.developsEnhanced Delivery Oligonucleotide99% confidence2 sources
- PepGen Inc.employsNoel Donnelly99% confidence1 source
- PepGen Inc.employsPaul Streck99% confidence1 source
- PepGen Inc.employsJames McArthur99% confidence1 source
- PepGen Inc.funded byPepGen $125 Million Public Offering November 202694% confidence1 source
Relationship
PepGen Inc.developsPGN-EDODM1
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 12, 2026PepGen Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
PepGen is advancing PGN-EDODM1, a clinical candidate
- filingSEC EDGARNov 10, 2026PepGen Inc. 8-K: Item 2.02: Results of Operations and Financial Condition; Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
PepGen Inc. is advancing PGN-EDODM1, a clinical candidate for the treatment of myotonic dystrophy type 1